

Press Release

Joachim Weith
Senior Vice President
Corporate Communications
and Governmental Affairs

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2101
F +49 6172 608-2294
Joachim.Weith@fresenius.com
www.fresenius.com

December 2, 2011

Fresenius Kabi announces Changes in the Management Board

The Supervisory Board of Fresenius Kabi AG today announced changes in the Management Board of Fresenius Kabi. Effective March 1, 2012 Mats Henriksson, who serves as Member of the Management Board of Fresenius Kabi AG and President of the region Asia Pacific, will be promoted to Deputy Chairman of the Management Board of Fresenius Kabi AG. On January 1, 2013 Mats will succeed Rainer Baule as President and CEO of the Management Board of Fresenius Kabi AG. The appointment of Mats Henriksson is part of the company's succession plan to ensure a smooth transition of leadership.

Effective March 1, 2012 Thomas Mechtersheimer, who has been Senior Vice President for Fresenius Medical Care South Asia Pacific, will join the Fresenius Kabi AG Management Board as Deputy Member and will assume the position of President of region Asia Pacific. As of January 1, 2013 Thomas Mechtersheimer will become a full Member of the Management Board of Fresenius Kabi AG.

Since May 2001, Rainer Baule has been responsible for Fresenius Kabi, the second largest business segment within Fresenius, specialized in i.v. drugs, infusion therapies and clinical nutrition for the hospital and the outpatient care. Over the course of his tenure, company sales tripled and the geographic footprint expanded substantially. Today, Fresenius Kabi counts among the leading companies in its business segments worldwide. Rainer, who turned 63 this year, joined Fresenius in 1997 as President of the former Fresenius HemoCare business segment and

Member of the Management Board of Fresenius, before he took over the responsibility for Fresenius Kabi.

Mats Henriksson joined the company in 1999 as Member of the Management Board of Fresenius Kabi AG. Since 2001, he has been President of the region Asia Pacific. Under his leadership, Fresenius Kabi has seen continued strong growth in this region, which is proven by No 1 or No 2 market positions in most countries in Asia Pacific.

Before joining the company, Mats held several controlling and finance positions at Pharmacia & Upjohn. At the end of 1998, Pharmacia & Upjohn divested its Clinical Nutrition business to Fresenius and Mats became the Chief Financial Officer and Member of the Management Board of Fresenius Kabi AG. He is a Swedish citizen and studied Business Administration and Economics at the Gothenburg School of Economics, Sweden.

Thomas Mechttersheimer has been Senior Vice President for Fresenius Medical Care South Asia Pacific since 2007 and currently reports directly to Roberto Fusté, Chief Executive Officer of Fresenius Medical Care Asia Pacific. Over the years, Thomas significantly contributed to the growth of Fresenius Medical Care in Asia and has a deep understanding of the Asian market dynamics. Thomas joined Fresenius in 1995 and has since held several executive positions within the Asian organization. Prior to joining Fresenius Medical Care, he worked in Industrial Automation and Special Machinery companies, both in Sales as well as in Technical Services. Thomas studied International Business at the Reutlingen University, Germany.

Rainer Baule, CEO and President of Fresenius Kabi AG, said: "We are very pleased with the appointments of Mats as my successor and Thomas as new Board Member of Fresenius Kabi. Mats has an outstanding track record of results-oriented performance and successful management experience within Fresenius Kabi. This qualifies him perfectly to serve as CEO and President of Fresenius Kabi. Thomas is an excellent successor of Mats. With his extensive experience and his profound knowledge of the Asian Pacific market, I am confident Thomas will make significant contributions to continue the successful growth of Fresenius Kabi's business in this region. I look forward to working closely with both."

Ulf Mark Schneider, CEO of Fresenius and Chairman of the Supervisory Board of Fresenius Kabi AG, said: "Under Rainer Baule's leadership, Fresenius Kabi has grown significantly and developed into a global player in health care. This is the

right time to begin a smooth transition of leadership. We are pleased to elevate Mats Henriksson to the new position of Deputy Chairman of Fresenius Kabi's Management Board. Building on his significant accomplishments in Asia Pacific, this role will prepare Mats for succeeding Rainer in leading the company. Thomas Mechtersheimer brings valuable international management experience and a deep understanding of the health care market dynamics that will be essential for the continued growth of our Fresenius Kabi business in Asia Pacific. Both appointments come from within Fresenius and this reflects the strength and depth of our management team. I am confident that Rainer, Mats and Thomas, along with their colleagues of the Fresenius Kabi Management Board, will continue to successfully grow the company".

New Management Board of Fresenius Kabi by March 1, 2012:

Rainer Baule

Chief Executive Officer (CEO) and Chairman of the Management Board

Mats Henriksson

Deputy Chairman of the Management Board

Marc Crouton

President of Region West & South Europe, Latin America & Africa

John Ducker

President Region North America

Manfred M. Köhler

President of Region Central/Eastern Europe, Nordics & Middle East

Thomas Mechtersheimer

Deputy Member and President Region Asia Pacific

Dr. Michael Schönhofen

President Science, Production & Technology

Gerrit Steen

Chief Financial Officer

#

Fresenius Kabi is the market leader in infusion therapy and clinical nutrition in Europe and holds leading positions in important countries of Latin America and the Asia-Pacific region. Within I.V. generic drugs, Fresenius Kabi counts among the leading suppliers in the US market. Fresenius Kabi is focused on the therapy and care of critically and chronically ill patients inside and outside the hospital. Its portfolio comprises a wide range of IV drugs, infusion therapies, clinical nutrition products as well as the related medical devices. With a corporate philosophy of "caring for life," the company's goal is to improve the patient's quality of life.

Fresenius Kabi has 24,057 employees worldwide (September 30, 2011). In 2010, Fresenius Kabi's sales were €3,672 million and the company's EBIT was €737 million. Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE & Co. KGaA.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Management Board: Rainer Baule (Chairman), Marc Crouton, John Ducker, Mats Henriksson, Manfred M. Köhler, Dr. Michael Schönhofen, Gerrit Steen
Chairman of the Supervisory Board: Dr. Ulf M. Schneider
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11654